The development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy. We reviewed 17 cases with etoposide-related acute promyelocytic leukemia (APL) reported in the literature. The close association between treatment with etoposide for Langerhans cell histiocytosis (LCH) and the development of etoposide-related APL was demonstrated among Japanese and Italians. Our data on the breakpoints (b/ps) of the PML and RAR␣ genes are presented. It is suggested that chromatin structure might be more important than specific consensus sequence in the distribution of b/ps in etoposide-related APL. Keywords: acute promyelocytic leukemia; therapy-related leukemia; etoposide; PML-RAR␣; Langerhans cell histiocytosis
Etoposide-related acute promyelocytic leukemia
The development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy.
From the beginning, alkylating agents and radiation have been suspected as the cause of t-AML. In 1991, compared with chemotherapy including alkylating agents, etoposideassociated secondary leukemia was characterized by the following: a shorter latency period, the absence of prolonged myelodysplasia, an M4 or M5 phenotype, and abnormalities of chromosome band 11q23. 1, 2 Among the patients with etoposide-related AML, Pedersen-Bjergaard et al [3] [4] [5] [6] [7] revealed a high frequency of translocations involving chromosome band 11q23 and 21q22. More recently, t-AML with other balanced translocations such as t (15;17) , t(8;21), inv (16) , t (8;16) , and t(9;22) was also reviewed. 8, 9 Since the initial case reports in the 1980s of t-AML following treatment with etoposide, more than 150 such instances have been reported.
Topoisomerase-II inhibitors and therapy-related acute myeloid leukemia
Etoposide, inhibitor of the intranuclear enzyme topoisomerase-II (Topo-II), has been used widely as an anticancer drug. Topo-II is able to pass one DNA duplex through another by introducing double-strand breaks in a DNA segment. Normally, the DNA strand breaks produced by Topo-II are quickly resealed. However, in the presence of Topo-II inhibitors the strand breaks persist and the enzyme/DNA complex remains Correspondence: T Naoe, Department of Infectious Diseases, Nagoya University Hospital, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; Fax: 81 52 744 2801 Received 24 October 1997; accepted 9 April 1998 stable. 10 It was proposed that nonhomologous recombination, which was mediated by Topo-II, resulted in chromosomal translocations involving cellular oncogene.
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The DNA cleavage sites by Topo-II were studied in vitro using naked DNA, and a consensus sequence has been proposed. 12, 13 However, when the cleavage sites were studied in cultured CCRF-CEM cells exposed to etoposide, they seemed to be associated with the V(D)J recombinase recognition sequences of intron 1 and 3 of the hypoxanthine phosphoribosyltransferase (hprt) gene. 14, 15 Site-specific cleavage of the AML1 gene at 21q22 induced by etoposide were also studied using MOLT-4 cell lines, and a 16/18 match for the Topo-II consensus sequence was identified close to the site-specific cleavage site. Similar site-specific cleavage could not be detected within RAR␣ intron 2. 16, 17 Among patients with etoposide-related AML, chromosomal translocations involving chromosome band 11q23 have been frequently observed. 18 11q23 rearrangements are found in de novo acute leukemia (monocytic, myelomonocytic, mixed or undifferentiated) as well as in t-AML, and coupled with more than 12 partner chromosomal regions. The breakpoints (b/ps) are clustered within the MLL genes. The b/ps of 74% of de novo leukemia map to the centromeric half of the MLL bcr, while the b/ps of 75% in t-AML map to the telomeric half, which contains both the high-affinity scaffold attachment regions (SARS) and the topoisomerase II sites. Thus, the chromatin structure of the MLL bcr might be significant, and it has also been mentiond that the mechanism leading to translocations might differ in de novo leukemia and in t-AML.
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Etoposide-related acute promyelocytic leukemia
Detourmignies et al 20 showed 16 cases with t-APL in 1992, then in 1996 Wiernik and Muse 21 reviewed 51 cases with t-APL, seven of whom had a history of prior chemotherapy regimens including etoposide. Rosner and Grunwald 22 found 19 cases of t-APL among 1303 published cases of t-AML (1.4%). In Japan, 19 cases of t-APL were found among 256 cases of t-AML (7.4%). Eleven of the 19 cases were treated with etoposide, including three cases after exposure to single-agent etoposide. 23 Clinical profiles of 17 cases with etoposide-related APL reported in the literature are given in Table 1 . 20, 21, [24] [25] [26] [27] [28] [29] [30] [31] [32] The close association was demonstrated between the treatment with etoposide for Langerhans cell histiocytosis (LCH) and the development of t-APL. The primary tumor was a LCH in nine cases; in three of four Japanese patients and four of five Italian patients, no therapeutic agents other than prednisolone and vinblastin had been used in addition to etoposide. To our knowledge, no cases with LCH preceding etoposiderelated APL have been diagnosed among subjects of AngloSaxon origin. This may suggest that the development of t-APL is specific to genetic factors among different ethnic groups. Ten of 17 cases had the karyotype of t(15;17) and some of them responded to all-trans-retinoic acid (ATRA) therapy similar to de novo APL. Four pediatric patients were in complete remission after bone marrow transplantation. The patients with t-APL are generally observed to respond favorably to ATRA and intensive antileukemic chemotherapy. 33 APL is characterized by a reciprocal translocation that involves the PML gene on chromosome 15 and the RAR␣ gene on chromosome 17. The b/ps of the RAR␣ gene are consistently localized within intron 2, and those of the PML gene are clustered in two regions separated by about 10 kb, namely intron 3 (known as bcr 3) and around intron 6 (bcr 1 and 2). 34 In the former, the so-called 'short-type' transcript has been detected by reverse-transcriptase polymerase chain reaction (RT-PCR) amplification. In the latter, the 'long-type' transcript has been observed. In de novo APL, bcr 1, 2, and 3 of the PML gene are disrupted in 65, 5 and 30% of the cases, respectively, according to a previous report. 35 On the other hand, the b/ps of the RAR␣ gene are randomly distributed in intron 2 ( Figure  1 ). There was no cluster of the b/ps within the introns, and no consensus-sequence motif was found around them. Identical stretches of one to seven nucleotides were observed between the PML and RAR␣ genes in the majority of the joining sequences. These data provide a potential model of the t(15;17) translocation: random DNA double-strand cleavage, modification of DNA ends, and single-strand base-pairing within identical short stretches. However, the molecular basis for the position of the breakpoint cluster regions has not been clarified in t-APL. 32 To reveal the mechanisms of the translocation, we analyzed the b/ps of the PML and RAR␣ genes in the three patients according to 1-3 in Table 1 . Southern blot analysis of the PML gene was performed in three patients, and revealed the same pattern of rearrangement. 36 The b/ps of the three t-APL patients were determined in a 170 bp fragment of intron 6 of the PML gene, much as with de novo APL (Figure 1) . The b/ps of the RAR␣ gene were clustered in a 670 bp fragment of intron 2, which is 10 kb in size, 37 but those of de novo APL were widely distributed in intron 2 and dispersed the EcoRIBamHI fragment in only 6/99 (6%) patients. 35 The b/ps of RAR␣ intron 2 determined from der(17) was revealed to be very close in cases 1 and 3, differing by only 4 bp.
Neither topoisomerase II cleavage sites: [(A/G)N(T/C)NNCNNG(T/C)-NG(G/T)TN(T/C)N(T/C)] 12 nor [AC(G/A)T(G/A)CGCGCG(C/T)-A(C/T)GT]
13 were identified near the b/ps (Figure 2 ). Because etoposide inhibits the normal religation of doublestrand breaks in DNA, it would cause increased nonhomologous DNA recombination and leukemogenesis in vivo. Thus, the underlying mechanisms of etoposide-related APL may be different from those of de novo APL. Furthermore, our data suggests that chromatin structure might be more important than specific consensus sequence in the distribution of b/ps in etoposide-related APL.
Future directions
Several reports have shown that the risk of etoposide-related AML depends largely on the schedule of drug administration and high cumulative dose, 10,38-40 although the shape of the dose-response curve is not yet well-defined. Smith et al 10 summarized the following: (1) The several reports of children with ALL treated with etoposide have shown a relatively high risk of developing t-AML (5-12% cumulative risk) using high cumulative doses of these agents (the equivalent of 7200-19 900 mg/m 2 of etoposide) given either weekly or twice weekly. Similar cumulative doses of etoposide given either every other week to ALL patients or given on a daily × 4 schedule to non-Hodgkin's lymphoma patients appeared to be associated with lower rates of t-AML development. (2) Germ cell patients treated with relatively low cumulative doses of etoposide (usually 1500-2500 mg/m 2 ) have a low risk for developing t-AML (Ͻ1%). This low risk (when compared to the higher risk for children with ALL described above) could be a result of the lower cumulative doses or the use of the daily × 5 schedule.
In a stepwise Cox regression analysis on 35 cases with etoposide-related AML, two factors increased the risk of this complication: weekly or twice weekly administration of etoposide (P Ͻ 0.001), and the administration of asparaginase immediately before etoposide therapy (P Ͻ 0.001). 39 Since the start of etoposide use in 1987 in Japan, the number of patients with etoposide-related leukemia increased, but no cases with LCH preceding t-APL have been reported after 1993, 41 because of administration of the drugs at longer intervals and at lower cumulative doses. The close association between the treatment with etoposide for LCH and the development of t-APL was demonstrated among Japanese and Italians. There might be a genetic background in the development of t-APL used by etoposide in these populations. Etoposide has been shown to be a useful agent for the treatment of patients with high risk leukemia, solid tumors and multisystem LCH. The effects of etoposide on DNA recombination have previously been characterized as a double-edged sword. Further analysis of the chromosomal junctions would provide valuable data for understanding the underlying mechanisms of the translocation and of the clustering of the b/ps.
